{
  "$schema": "folio-library-entry/v1",
  "id": "10665-360861",
  "blocks": [
    {
      "id": "library/10665-360861/blocks/figure-img-p001-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-1.webp",
      "narrative": "draft",
      "content": "Cover photograph of a smiling woman with long reddish braided hair, wearing a red top.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/figure-img-p001-2",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-2.webp",
      "narrative": "draft",
      "content": "Cover photograph of a young woman in a green top and patterned wrap skirt standing outdoors under a cloudy sky at dusk, with trees behind her.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/figure-img-p001-3",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-3.webp",
      "narrative": "draft",
      "content": "Black-and-white cover photograph of a person applying eyebrow make-up while looking into a hand mirror.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/figure-img-p001-4",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-4.webp",
      "narrative": "draft",
      "content": "Cover photograph of a smiling young man in a dark blue T-shirt against a dark background.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/figure-img-p001-5",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-5.webp",
      "narrative": "draft",
      "content": "Cover photograph of a smiling young woman wearing a teal jacket over a black T-shirt with green lettering.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/figure-img-p001-6",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-6.webp",
      "narrative": "draft",
      "content": "Cover photograph of a smiling man with a beard and a cap, sitting on a bed with a striped cover in front of a dark painted wall.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 5,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "Differentiated and \nsimplified pre-exposure \nprophylaxis for HIV \nprevention\nUpdate to WHO implementation guidance\nTECHNICAL BRIEF\nUpdate to WHO implementation guidance\nTECHNICAL BRIEF\nDifferentiated and \nsimplified pre-exposure \nprophylaxis for HIV \nprevention\nDifferentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance. \nTechnical Brief\nISBN 978-92-4-005369-4 (electronic version)  \nISBN 978-92-4-005370-0 (print version)\n© World Health Organization 2022\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The cover, title and copyright pages of the 2022 WHO technical brief on differentiated and simplified pre-exposure prophylaxis (PrEP) for HIV prevention, with ISBNs and licence terms. It gives the suggested citation and disclaimers. A table of contents lists sections on delivering PrEP, research gaps and annexes on HIV self-testing modelling in Kenya, a global PrEP provider study and PrEP for people who inject drugs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 5,
      "pageEnd": 7,
      "target": "../sections/sec-000-acknowledgements.md",
      "narrative": null,
      "content": "External contributors\nWHO would like to thank the following external \ncontributors to this brief who participated in technical \nconsultations and provided and reviewed content: \nChris Akolo (FHI 360, United States of America (USA)), \nAdam Akullian (Institute for Disease Modeling, USA), \nPedro Henrique Amparo da Costa Leite (Fiocruz, \nBrazil), Lynsey Boyd (Sandyford Sexual Health Services, \nNHS Greater Glasgow & Clyde, United Kingdom of \nGreat Britain and Northern Ireland), Sylvain Chawki \n(Hôpital Saint-Louis et Lariboisière, France), Teddy \nCook (ACON, AusPATH and the Kirby Institute Universi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The acknowledgements of the technical brief on differentiated and simplified PrEP, listing external contributors from research institutions, programmes and organizations in many countries. It notes grant funding from Unitaid, the Bill & Melinda Gates Foundation and USAID.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Abbreviations",
      "pageStart": 7,
      "pageEnd": 8,
      "target": "../sections/sec-001-abbreviations.md",
      "narrative": null,
      "content": "ART\t\nantiretroviral therapy\nCAB-LA\t\nlong-acting injectable cabotegravir\nDVR\t\ndapivirine vaginal ring\nED-PrEP\t\nevent-driven PrEP\neGFR\t\nestimated glomerular filtration rate\nFTC\t\nemtricitabine\nGFR\t\nglomerular filtration rate\nHBsAg\t\nHBV surface antigen\nHBV\t\nhepatitis B virus\nHCV\t\nhepatitis C virus\nHIV\t\nhuman immunodeficiency virus\nHIVST\t\nHIV self-testing\nMMD\t\nmulti-month dispensing\nNRTI\t\nnucleoside reverse transcriptase inhibitor\nPEP\t\npost-exposure prophylaxis\nPrEP\t\npre-exposure prophylaxis\nRCT\t\nrandomized controlled trial\nRDT\t\nrapid diagnostic test\nSTI\t\nsexually transmitted infection\nTDF\t\ntenofov",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of abbreviations used in the PrEP technical brief, such as CAB-LA, ED-PrEP, HBsAg and TDF.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Overview",
      "pageStart": 8,
      "pageEnd": 10,
      "target": "../sections/sec-002-overview.md",
      "narrative": null,
      "content": "What is this technical brief?\nThis technical brief by the World Health Organization \n(WHO) updates and supplements previous WHO \nguidelines and guidance on pre-exposure prophylaxis \n(PrEP) for HIV prevention. The brief aims to support \ndifferentiated, simplified, demedicalized and \ncomprehensive PrEP services. This can support PrEP \nuptake, persistence and effective use and assist efforts \nto achieve global goals set out in the 2022–2030 Global \nHealth Sector Strategies on HIV, viral hepatitis and \nsexually transmitted infections. Further updates to \nWHO PrEP implementation guidance are expect",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives an overview of the technical brief, which updates WHO guidance to support differentiated, simplified, demedicalized PrEP services in line with the 2022–2030 global health sector strategies. It lists key points on starting and stopping oral PrEP, including event-driven dosing for people assigned male at birth not taking estradiol-based hormones, and on hepatitis B and C testing. It also introduces the four building blocks of differentiated delivery: where, who, when and what.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../sections/sec-003-introduction.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 10,
      "pageEnd": 11,
      "target": "../sections/sec-004-background.md",
      "narrative": null,
      "content": "Pre-exposure prophylaxis (PrEP) for HIV prevention \nis the use of antiretroviral drugs by HIV-negative \nindividuals to reduce the risk of acquisition of \nHIV. The World Health Organization (WHO) has \nrecommended multiple PrEP options as part of \ncombination prevention approaches (Box 1). When \nWHO recommended offering TDF-based oral PrEP \nto people at substantial risk for HIV in 2015 (Box 2), \nimplementation of PrEP services was largely limited \nto small-scale studies and projects and high-income \nsettings. Given the limited experience, WHO followed \na cautious “do no harm” principle when deve",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains what PrEP is and recalls that WHO's 2015 recommendation of TDF-based oral PrEP was cautious because experience was limited, whereas services have since been widely simplified, demedicalized and integrated. It states the brief's aim of supporting these trends, accelerated by COVID-19, towards the UN target of fewer than 370 000 new infections by 2025, and summarises WHO PrEP recommendations in a box.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Target audience and scope",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/sec-005-target-audience-and-scope.md",
      "narrative": null,
      "content": "This technical brief aims to support a range of \nstakeholders in planning and implementing PrEP \nservices. It provides guidance on PrEP implementation \nand is meant to supplement and update guidance \npreviously published in the WHO Consolidated HIV \nGuidelines (4) and the WHO PrEP Implementation Tool.3 \nThe guidance in this document relates primarily to \nTDF-based oral PrEP (including TDF in combination with \nemtricitabine [FTC] or lamivudine [3TC]) as most of the \nimplementation experience and evidence available is \nfor oral PrEP. Key principles of the guidance will also \nbe applicable to oth",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the brief's audience and scope: it supplements WHO consolidated HIV guidelines and the PrEP Implementation Tool, focusing on TDF-based oral PrEP while noting considerations for the dapivirine vaginal ring and long-acting cabotegravir.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Guiding principle and methodology",
      "pageStart": 11,
      "pageEnd": 12,
      "target": "../sections/sec-006-guiding-principle-and-methodology.md",
      "narrative": null,
      "content": "This technical brief follows a public health, human \nrights and people-centred approach to provide \nevidence-based guidance on PrEP service delivery. \nSuch an approach puts the people and communities \nwho could benefit from PrEP services at the centre of \nservice delivery, adapting services to their preferences \nand needs while maximizing impact and health system \nefficiency. \nThe development of this brief was led by a core group \nof staff members and consultants of the Testing, \nPrevention and Populations unit of the Global \nHIV, Hepatitis and Sexually Transmitted Infections \nProgrammes of WH",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the brief's people-centred, rights-based approach and how it was developed by a WHO core group with an expert working group, including management of declarations of interest. It also begins guidance that eligible people assigned male at birth may choose event-driven or daily oral PrEP, with a footnote defining transgender people.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Starting, using and stopping oral PrEP",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/sec-007-starting-using-and-stopping-oral-prep.md",
      "narrative": null,
      "content": "stopping oral PrEP",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A heading fragment for the section on starting, using and stopping oral PrEP.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Oral event-driven PrEP (ED-PrEP)",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/sec-008-oral-event-driven-prep-ed-prep.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Starting and stopping oral PrEP",
      "pageStart": 12,
      "pageEnd": 14,
      "target": "../sections/sec-009-starting-and-stopping-oral-prep.md",
      "narrative": null,
      "content": "To reduce the risk of HIV acquisition through sexual \nexposure, cisgender men and trans and gender diverse \npeople assigned male at birth4 who are not taking \nexogenous estradiol-based hormones may be offered \noral daily PrEP or ED-PrEP as options (Table 1 and \nFigure 1). Whether the intention is to use oral daily PrEP \nor ED-PrEP, people eligible for ED-PrEP can start and \nstop PrEP using the same strategy:\n•\t Start PrEP with two doses (loading dose) of TDF-\nbased oral PrEP taken between 2 and 24 hours before \nsexual exposure. Ideally, this loading dose should be \ntaken closer to 24 hours bef",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out how to start and stop oral PrEP: people eligible for event-driven PrEP take a double loading dose 2–24 hours before sex and continue daily until two days after the last exposure. All other groups, including cisgender women and people who inject drugs, take seven daily doses before protection and stop seven days after the last exposure. A figure illustrates the dosing timelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/figure-vfig-p013",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../figures/vfig-p013.webp",
      "narrative": "draft",
      "content": "Page render with the end of Table 1 and Figure 1. The table gives oral PrEP dosing by population: cisgender men and trans and gender diverse people assigned male at birth with sexual exposure who are not taking exogenous estradiol-based hormones take a double dose 2–24 hours before exposure, one dose per day, and one dose per day until two days after the last exposure; other populations (including cisgender women, people taking estradiol-based hormones and people preventing HIV acquisition from injecting practices) take one dose daily for seven days before exposure, one dose per day, and one dose daily for seven days after the last exposure. Figure 1 shows day-by-day timelines with pill icons: for those eligible for ED-PrEP, a double dose then daily doses through two days after sex (within or beyond 24 hours of the initial dose); for those not eligible, seven daily doses before exposure, continued daily dosing, and seven daily doses after the last exposure.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Starting, using and stopping TDF-based oral PrEP safely",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "How to start, use and stop TDF-based oral PrEP for two groups: people assigned male at birth with sexual exposure who are not taking estradiol-based hormones (eligible for a double starting dose), and all other populations, including people assigned female at birth, those taking estradiol-based hormones and people who inject drugs (seven-day lead-in and stopping periods).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale",
      "pageStart": 14,
      "pageEnd": 15,
      "target": "../sections/sec-010-rationale.md",
      "narrative": null,
      "content": "Data from trials, open label extension studies and \ndemonstration studies have shown that oral PrEP using \nthe ED-PrEP dosing regimen is as effective in preventing \nHIV infection as daily PrEP in cisgender men who have \nsex with men (6–8). As a result, WHO recommended \nthat an ED-PrEP regimen is safe and highly effective in \nreducing risk of HIV acquisition through receptive and/\nor insertive sex between cisgender men and can be \noffered as an alternative to daily dosing for men who \nhave sex with men (6). Importantly, ED-PrEP is effective \nfor all positioning (insertive and/or receptive). It",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the evidence that event-driven PrEP is as effective as daily PrEP for cisgender men who have sex with men and why it can be extended to all people assigned male at birth not taking estradiol-based hormones, regardless of sexual positioning. It notes insufficient evidence for other groups and compares lead-in and stopping times recommended in other guidelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PrEP and hepatitis B and C",
      "pageStart": 15,
      "pageEnd": 15,
      "target": "../sections/sec-011-prep-and-hepatitis-b-and-c.md",
      "narrative": null,
      "content": "B and C\n▶ HBsAg test is non-reactive: WHO recommends HBV \nvaccination for people at risk of acquiring HBV (25).5 \n▶ HBsAg test is reactive: Further assessment for HBV \ntreatment eligibility. \n•\t Eligibility for long-term therapy for HBV infection \nas per WHO guidance (26): \n\t– People with detectable HBsAg and clinical \nevidence of compensated or decompensated \ncirrhosis.\n\t– People older than 30 years with persistently \nabnormal alanine aminotransferase (ALT) levels \nand evidence of high-level HBV replication \n(who do not have clinical evidence of cirrhosis).\n•\t WHO recommends TDF or entecavir",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives a flowchart-style summary of hepatitis B management in PrEP services: vaccination for those testing HBsAg-negative and assessment for treatment for those positive. It explains that TDF-based PrEP also suppresses hepatitis B, notes the small risk of relapse after stopping and the need for monitoring.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Hepatitis B virus",
      "pageStart": 15,
      "pageEnd": 16,
      "target": "../sections/sec-012-hepatitis-b-virus.md",
      "narrative": null,
      "content": "Testing PrEP users for HBsAg once, at or within one to \nthree months of PrEP initiation (or later if not available \naround initiation), is strongly encouraged, particularly \nin highly endemic countries. TDF-based daily or event-\ndriven oral PrEP and the DVR can be safely offered \nto persons with HBV infection. There are specific \nconsiderations regarding offering CAB-LA to people \nwith HBV (Box 3). HBV testing is not a requirement for \nPrEP use. Therefore, lack of HBV testing should not be \na barrier to PrEP initiation or use. Where HBV testing \nis conducted, PrEP can be initiated before resul",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends testing PrEP users once for hepatitis B surface antigen, especially in highly endemic countries, while stressing that lack of testing must not delay PrEP. It notes that oral PrEP and the dapivirine ring are safe for people with hepatitis B or C and repeats the key points on hepatitis testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Hepatitis C virus",
      "pageStart": 16,
      "pageEnd": 17,
      "target": "../sections/sec-013-hepatitis-c-virus.md",
      "narrative": null,
      "content": "HCV antibody testing is strongly encouraged at or \nwithin one to three months of PrEP initiation (or \nlater if not available around initiation), and every 12 \nmonths thereafter, where PrEP services are provided to \npopulations at high risk of HCV infection. Risks of HCV \nvary across settings, and populations at high risk of \nHCV include, but are not limited to, cisgender men and \ntransgender women who have sex with men, people \nwho use drugs, and people in prisons and other closed \nsettings. TDF-based daily or event-driven oral PrEP \nand the DVR can be safely offered to persons with HCV \ninfec",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends hepatitis C antibody testing at PrEP start and yearly for populations at high risk, while making clear that testing is not a requirement for PrEP. It covers referral for treatment, HCV self-testing and specific considerations for long-acting cabotegravir in people with hepatitis C.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale",
      "pageStart": 17,
      "pageEnd": 18,
      "target": "../sections/sec-014-rationale.md",
      "narrative": null,
      "content": "WHO estimates that in 2019, there were 296 million \npeople living with chronic HBV infection and 58 \nmillion people living with HCV infection worldwide \n(31). An estimated 1.1 million deaths in 2019 were due \nto HBV and HCV infection. The Global Health Sector \nStrategy on Viral Hepatitis, approved by the World \nHealth Assembly in 2016, set the goal to eliminate viral \nhepatitis as a major public health threat by 2030 (32). \nHBV and HCV are endemic in many parts of the world \nwhere there is also a high burden of HIV, and many key \nand vulnerable populations are affected by both HIV \nand viral h",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the rationale for the hepatitis guidance, citing global estimates of hepatitis B and C burden and the 2030 elimination goal. It revises earlier advice by stating that hepatitis B infection does not rule out event-driven PrEP, because clinical relapse is rare, and discusses PrEP choices for pregnant people living with hepatitis B.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PrEP and kidney function",
      "pageStart": 18,
      "pageEnd": 20,
      "target": "../sections/sec-015-prep-and-kidney-function.md",
      "narrative": null,
      "content": "Impaired kidney function, indicated by an eGFR of \n<60 mL/min per 1.73 m2 or an estimated creatinine \nclearance of <60 mL/min, is a contraindication for the \nuse of TDF-based oral PrEP. Measuring kidney function \nin potential PrEP users at initiation and during PrEP \ncontinuation is suggested for some populations. Table \n2 outlines suggested procedures (applicable to oral \ndaily PrEP or ED-PrEP). Box 4 provides suggestions on \nestimating kidney function. \nWaiting for a kidney function test result should not \ndelay initiation or continuation of oral PrEP, as results \ncan be reviewed at follow-u",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out guidance on kidney function and TDF-based oral PrEP: impaired kidney function is a contraindication, but testing is optional for people under 30 without comorbidities and can be limited for others. It advises that waiting for results should not delay PrEP and that tests be repeated before stopping. Notes cover estimating kidney function, including during pregnancy and gender-affirming hormone use.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2. Suggested procedures for measuring kidney function for TDF-containing oral PrEP",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "Suggested kidney function testing at PrEP initiation and at follow-up for people taking TDF-containing oral PrEP, by population group defined by age (under 30, 30–49, 50+), kidney-related comorbidities and previous evidence of reduced kidney function.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../sections/sec-016-rationale.md",
      "narrative": null,
      "content": "Multiple systematic reviews and meta-analyses \nof randomized controlled trials (RCTs) found that \nindividuals taking TDF-based oral PrEP have, on \naverage, a higher risk of experiencing kidney-related \nadverse events compared with individuals taking \nplacebos (46–48), but these adverse events tend to \nbe mild, nonprogressive, and reversible after PrEP \ndiscontinuation. Severe kidney-related adverse \nevents are very rare. An analysis of data from 17 \nimplementation projects and two clinical trials from \n15 countries found that less than 1% of over 18 000 \nindividuals screened for PrEP had abnor",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the rationale for reduced kidney testing, citing meta-analyses showing mostly mild, reversible kidney effects and data from over 18 000 people screened in which abnormal values were rare and increased with age.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV self-testing (HIVST) for PrEP",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-017-hiv-self-testing-hivst-for-prep.md",
      "narrative": null,
      "content": "(HIVST) for PrEP",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A heading fragment for the section on HIV self-testing for PrEP.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIVST and PrEP",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-018-hivst-and-prep.md",
      "narrative": null,
      "content": "HIVST could be an important tool to enable countries \nto increase access to PrEP and uptake, persistence \nand effective use. Since the beginning of the COVID-19 \npandemic, WHO has supported HIVST to maintain PrEP \nservices (51), and several countries have integrated \nHIVST into their PrEP programming to initiate and \ncontinue clients on PrEP (see Box 6 and 10 in next \nsection). A literature review found evidence that HIVST \ncan reduce clinic visits for oral PrEP continuation and \nsupport HIV testing between clinic visits, and may \nincrease PrEP use in some groups (52). Experience \nduring COVID",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how HIV self-testing can support PrEP, drawing on COVID-19 experience and a review showing fewer clinic visits and testing between visits. It outlines three uses—demand generation and linkage, PrEP initiation, and continuation—and notes the need for community engagement and further operational research.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "What is HIVST?",
      "pageStart": 21,
      "pageEnd": 23,
      "target": "../sections/sec-019-what-is-hivst.md",
      "narrative": null,
      "content": "In HIVST, people collect their own specimen (generally \noral fluid or fingerprick whole blood) using a simple \nrapid HIV test and then perform the test and interpret \ntheir result, often in private or with someone they \ntrust. WHO has recommended HIVST as an approach \nto HIV testing services since 2016 (4), and the approach \nhas been scaled up globally with nearly 100 countries \nreporting national policies.6 Currently, there are five \nWHO prequalified HIVST products available,7 all of \nwhich have been shown to be highly accurate and \nachieve good performance (49). In field settings, HIVST \nhas",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains what HIV self-testing is, its WHO recommendation since 2016 and the prequalified products available. It discusses using self-testing to start PrEP outside clinics despite limited evidence, addressing concerns about acute infection and drug resistance. Modelling summarised here suggests that self-testing may miss some infections but that drug-resistance prevalence stays similar across scenarios.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale",
      "pageStart": 23,
      "pageEnd": 24,
      "target": "../sections/sec-020-rationale.md",
      "narrative": null,
      "content": "A systematic review on HIVST for PrEP initiation and \ncontinuation (52) identified three completed RCTs \nthat evaluated PrEP continuation after initiation in \nhealth care facilities, while no studies evaluated \nHIVST-based PrEP initiation. All studies evaluated \noral PrEP. An RCT in Kenya that evaluated six-month \nPrEP dispensing supported with HIVST between clinic \nvisits found that PrEP clinic visits were halved, while \nPrEP persistence and use were similar to standard-\nof-care three-month PrEP dispensing and clinic-\nbased HIV testing. PrEP use was significantly higher \namong women not in se",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises a systematic review of self-testing for PrEP, including a Kenyan trial in which six-month dispensing with self-testing halved clinic visits without reducing persistence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Building blocks of differentiated PrEP service delivery",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-021-building-blocks-of-differentiated-prep-service-d.md",
      "narrative": null,
      "content": "delivery\nIn many countries, individuals interested in PrEP \nmust go to a health care facility (often an HIV clinic) \nto obtain a prescription from a medical provider \n(often a physician). In recent years, and particularly \nduring the COVID-19 pandemic (60), the shift towards \ndifferentiated PrEP service delivery has accelerated.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces differentiated PrEP delivery, noting the shift away from clinic-only physician prescribing that accelerated during COVID-19.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Differentiated PrEP service delivery: When, where, who and what to deliver",
      "pageStart": 24,
      "pageEnd": 25,
      "target": "../sections/sec-022-differentiated-prep-service-delivery-when-where.md",
      "narrative": null,
      "content": "delivery: When, where, who \nand what to deliver\nA differentiated PrEP service delivery approach \nis person- and community-centred and adapts \nservices to the needs and preferences of the people \nwho are interested in and could benefit from PrEP. \nDifferentiated PrEP service delivery may also support \nmore efficient and cost–effective use of health care \nresources. WHO recommends differentiated service \ndelivery for HIV testing and antiretroviral therapy \n(ART) (4). Delivery of person-centred health services is \none of the key strategic directions of the global health \nsector strategies on HIV,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines differentiated PrEP service delivery as person- and community-centred and links it to the global health sector strategies. It presents the four building blocks (when, where, who and what), which can differ between initiation, continuation and re-initiation and across PrEP products.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Where to deliver PrEP",
      "pageStart": 25,
      "pageEnd": 27,
      "target": "../sections/sec-023-where-to-deliver-prep.md",
      "narrative": null,
      "content": "There are a range of barriers to PrEP access, uptake, \npersistence and effective use associated with service \ndelivery in health care facilities. These include actual \nor perceived lack of privacy, stigma and discrimination, \nnegative attitudes of health care providers, travel \ndistance, direct and opportunity costs for clients, \nfrequency of required clinic visits for continuation, \nlengthy waiting times and inconvenient operating \nhours. Provider-level barriers include policy and \nlegal barriers (for example, policies restricting \neligibility), lack of training, understaffing, limited \ntime",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out barriers to PrEP in health facilities, such as stigma, lack of privacy, distance, costs and long waits, as well as provider-side barriers. It argues that oral PrEP and the ring have few required components and can be delivered in community settings, while more research is needed for long-acting cabotegravir. Evidence and provider views on community-based delivery follow.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3. The building blocks of differentiated PrEP service delivery",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../tables/table-3.csv",
      "narrative": "draft",
      "content": "Framework for differentiated PrEP service delivery: for each building block (where, who, when, what), the table names what has to be defined at initiation, initial follow-up and re-initiation, and during continuation (PrEP refills and follow-up).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PrEP in fixed and mobile community settings",
      "pageStart": 27,
      "pageEnd": 29,
      "target": "../sections/sec-024-prep-in-fixed-and-mobile-community-settings.md",
      "narrative": null,
      "content": "Service models that deliver oral PrEP in fixed \ncommunity sites (such as through nongovernmental \norganizations) and mobile and semimobile sites (for \nexample, vans parked in community settings) have \nbeen implemented. A systematic review (Box 7) (63) \nidentified diverse models demonstrating the feasibility \nof these approaches in a range of countries, but data on \neffectiveness were limited. In addition to considerations \noutlined above, studies highlighted the need for \nstrong partnerships between mobile PrEP delivery \nsites and local community-based organizations. \nSame-day PrEP initiation",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes oral PrEP delivery in fixed and mobile community sites, such as NGO centres and vans, and the importance of partnerships with community organizations and integrated services. A box summarises review evidence, including the SEARCH trial in Kenya and Uganda and the Love O2O study in Thailand, and an example from Viet Nam is pictured.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/figure-img-p028-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../images/img-p028-1.webp",
      "narrative": "draft",
      "content": "Photograph (Fig. 2) of a white van in Dong Nai province, Viet Nam, wrapped in blue PrEP branding with two young men and the slogans 'I ♥ PrEP BUS', 'PrEP in our hands' and 'PrEP trong tầm tay', with bubbles reading 'PrEP' and 'ED-PrEP'.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/figure-vfig-p028",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../figures/vfig-p028.webp",
      "narrative": "draft",
      "content": "Render of Box 8, 'Bringing PrEP closer to home in Viet Nam', with its text on mobile PrEP and STI services and Fig. 2, a photograph of the blue-branded 'I ♥ PrEP BUS' van of the PrEP on Wheels programme in Dong Nai province (photo credit: PATH).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Telehealth for PrEP",
      "pageStart": 29,
      "pageEnd": 31,
      "target": "../sections/sec-025-telehealth-for-prep.md",
      "narrative": null,
      "content": "The use of information and telecommunication \ntechnologies to create virtual platforms for delivering \nPrEP services has the potential to remove barriers to \nPrEP uptake and persistence and support effective use \nof PrEP. WHO recommends that online delivery of HIV, \nviral hepatitis and STI services to key populations may \nbe offered as an additional option, while ensuring that \ndata security and confidentiality are protected (28). \nIn many countries, telehealth for PrEP has addressed \naccess challenges during the COVID-19 pandemic.8 A \nsystematic review identified a range of case studies of \nP",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes telehealth platforms for delivering PrEP, which WHO supports as an additional option provided data security and confidentiality are protected. It lists aspects of service delivery that telehealth can support, such as risk assessment, home delivery of self-test kits and prescriptions. Evidence from case studies and ongoing US trials is summarised, with a photo from a Brazilian project.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/figure-img-p030-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../images/img-p030-1.webp",
      "narrative": "draft",
      "content": "Photograph (Fig. 3) of a young man seen from behind at a round table, holding a phone or test device, with an opened prevention kit including a pink pouch, packets and a small bottle in front of him, and a plant and glasses on the table.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/figure-vfig-p030",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../figures/vfig-p030.webp",
      "narrative": "draft",
      "content": "Render of Box 10, 'Telehealth for PrEP during COVID-19 in Brazil', with its text on the ImPrEP and PrEP1519 projects and Fig. 3, a photograph of a PrEP1519 participant at home with an HIV prevention kit including an HIVST (photo credit: Project1519).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/figure-img-p031-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 31,
      "pageEnd": 31,
      "target": "../images/img-p031-1.webp",
      "narrative": "draft",
      "content": "Photograph (Fig. 4) of the entrance of a small pharmacy in Kenya with a sign reading 'SANAA PHARMACEUTICALS' and vertical signs reading 'DUKA LA DAWA' and 'CHEMIST', with shelves of products and posters inside.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/figure-vfig-p031",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 31,
      "pageEnd": 31,
      "target": "../figures/vfig-p031.webp",
      "narrative": "draft",
      "content": "Page render with the section 'PrEP delivery in pharmacies', Box 11 'Evidence about PrEP delivery in pharmacies', and Box 12 'Oral PrEP initiation and continuation in private pharmacies in Kenya', which includes Fig. 4, a photograph of the SANAA PHARMACEUTICALS shopfront (photo credit: Fred Hutch/Katrina Ortblad).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PrEP delivery in pharmacies",
      "pageStart": 31,
      "pageEnd": 32,
      "target": "../sections/sec-026-prep-delivery-in-pharmacies.md",
      "narrative": null,
      "content": "Pharmacies can be more accessible, acceptable and \nconvenient for clients than health care facilities. In \nresource-limited settings, individuals commonly first \nseek health care services from pharmacies before \ngoing to clinics (72,73). The WHO Guideline on Self-\nCare Interventions for Health and Well-Being (74) notes \nthat providing PrEP through pharmacies may present \nan opportunity to expand access to PrEP. However, \nfeasibility has only been demonstrated in a limited \nnumber of settings, and the effectiveness and cost–\neffectiveness of this model are unknown (Boxes 11 and \n12). To create",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that pharmacies can be more accessible and convenient than clinics and may expand PrEP access, though effectiveness and cost-effectiveness of pharmacy delivery remain unknown. It sets out what pharmacists need, such as legal authority, testing infrastructure and training, and cites Kenyan experience showing similar uptake and persistence, noting that legal changes are needed for pharmacists to prescribe PrEP.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Who to deliver PrEP",
      "pageStart": 32,
      "pageEnd": 33,
      "target": "../sections/sec-027-who-to-deliver-prep.md",
      "narrative": null,
      "content": "For HIV treatment, WHO recommends (4) that 1) \ntrained nonphysician clinicians, nurses and midwives \ncan initiate and maintain ART, and 2) trained and \nsupervised community health workers can dispense \nART and lay providers can distribute ART. For PrEP, in \nmost countries a clinician prescribes PrEP, while other \nhealth care providers (for example, lay providers) \nmay deliver other aspects of PrEP services, such as \nassessing whether individuals could benefit from \nPrEP or conducting HIV testing. Task sharing to enable \nPrEP delivery by a range of health workers, including \npeer and community",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Contrasts WHO task-sharing recommendations for ART with PrEP, which in most countries is prescribed by clinicians while lay providers handle other tasks such as risk assessment and HIV testing. It argues that sharing PrEP tasks with peers and community health workers may improve efficiency and acceptability, noting research needs for long-acting cabotegravir and requirements for training, quality assurance, clinical oversight and fair pay.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "When and what services to deliver",
      "pageStart": 33,
      "pageEnd": 35,
      "target": "../sections/sec-028-when-and-what-services-to-deliver.md",
      "narrative": null,
      "content": "Multi-month dispensing (MMD)\nWHO recommends that people living with HIV \nestablished on ART should be offered three-to-six–\nmonth ART refills, preferably lasting six months (4). \nMMD of ART has been found to be feasible and cost-\nsaving for providers and clients in a range of countries, \nand COVID-19 has accelerated adoption of ART MMD \n(83). For oral PrEP, a one-month supply is commonly \nprovided at initiation, requiring a one-month follow-up \nvisit. This is often appropriate, as it allows PrEP users to \ncheck in with their provider, review laboratory results \nas relevant, discuss issues or c",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses when and what PrEP services to deliver, starting with multi-month dispensing, which is standard for ART and is being adapted for PrEP after an initial one-month visit, with examples from Viet Nam, Zimbabwe and a Kenyan trial of six-month dispensing with HIV self-testing. It then covers integrating PrEP with other services, such as gender-affirming care, harm reduction, antenatal and family planning services, and a status-neutral approach to testing. It ends with a case study from Glasgow on PrEP for people who inject drugs, where staffing intensity limits expansion.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Research gaps",
      "pageStart": 35,
      "pageEnd": 36,
      "target": "../sections/sec-029-research-gaps.md",
      "narrative": null,
      "content": "While the feasibility of a range of differentiated PrEP \nservice delivery models has been demonstrated, \nadditional evidence of effectiveness of PrEP-related \noutcomes (uptake, persistence and effective use) \nis needed. Implementation science and quasi-\nexperimental approaches, such as difference-in-\ndifferences methods for pre–post evaluations of \ninterventions, could provide robust evidence on \neffectiveness, particularly since RCTs are often not \nfeasible and do not necessarily provide insight into real-\nworld implementation of services. Moreover, evidence \non feasibility of community-based",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies research gaps for differentiated PrEP delivery, calling for implementation science and quasi-experimental methods to measure effects on uptake, persistence and effective use. It notes that evidence is concentrated among men who have sex with men and young women in a few countries, and that experience with the dapivirine ring and long-acting cabotegravir is still lacking.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 36,
      "pageEnd": 42,
      "target": "../sections/sec-030-references.md",
      "narrative": null,
      "content": "1.\t\t\nSchaefer R, Schmidt HMA, Ravasi G, Mozalevskis \nA, Rewari BB, Lule F, et al. Adoption of guidelines \non and use of oral pre-exposure prophylaxis: a \nglobal summary and forecasting study. Lancet \nHIV. 2021;8(8):e502-e510. doi:10.1016/S2352-\n3018(21)00127-2\n2.\t\t\nPolitical declaration on HIV and AIDS: ending \ninequalities and getting on track to end aids by 2030. \nNew York City, NY: United Nations General Assembly; \n2021 (https://www.unaids.org/sites/default/files/\nmedia_asset/2021_political-declaration-on-hiv-\nand-aids_en.pdf, accessed 29 June 2022).\n3.\t\t\nGlobal health sector strategies on,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the technical brief on differentiated and simplified PrEP delivery, citing global HIV strategies, WHO HIV guidelines and studies of PrEP delivery models.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 1: Summary of mathematical modelling of HIVST for PrEP in Kenya",
      "pageStart": 42,
      "pageEnd": 43,
      "target": "../sections/sec-031-annex-1-summary-of-mathematical-modelling-of-hiv.md",
      "narrative": null,
      "content": "mathematical modelling  \nof HIVST for PrEP in Kenya\nBackground \nCommunity-based oral PrEP provision has the potential \nto expand PrEP access. HIVST can facilitate community-\nbased PrEP delivery by enabling non-health-care \nproviders to conduct HIV testing for PrEP initiation \nand continuation. However, HIVST can have lower test \nsensitivity than facility-based RDTs, potentially leading \nto inappropriate PrEP provision to persons living \nwith HIV. The overall health impact of HIVST for PrEP \ndelivery is not well understood.\nConclusions \nIncreasing PrEP coverage among sexually active \nindividual",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 1, summarizing mathematical modelling of HIV self-testing for community-based oral PrEP delivery in Kenya. It concludes that expanding PrEP could avert nearly half of new infections over 20 years and that self-testing-based delivery could be effective, with only small increases in inappropriate PrEP use and drug resistance compared with provider testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 2: Background and methods on the global PrEP provider study",
      "pageStart": 43,
      "pageEnd": 45,
      "target": "../sections/sec-032-annex-2-background-and-methods-on-the-global-pre.md",
      "narrative": null,
      "content": "methods on the global PrEP \nprovider study\nWHO supported a global study of PrEP providers, \ncomprising an online survey and in-depth interviews, \nfrom November 2021 through February 2022. The \nsurvey aimed to understand current service delivery \npractices as well as perspectives on new PrEP products. \nFollow-up interviews with survey participants were \nconducted to gain additional insights and to offer \nan opportunity for providers to raise other issues of \nconcern. An independent consultant in collaboration \nwith technical experts of WHO HHS led a consultative, \niterative process to formulate",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 2, describing the methods of a WHO-supported global survey and in-depth interviews of PrEP providers carried out between November 2021 and February 2022 on service practices and views of new PrEP products. It explains how questions were developed and translated and lists participating providers by WHO region and country.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table A2.1. Regional and country income level distribution of online survey participantsa,b",
      "pageStart": 43,
      "pageEnd": 43,
      "target": "../tables/table-a2-1.csv",
      "narrative": "draft",
      "content": "Distribution of online survey participants in the global PrEP provider study by WHO region and country income level (LMIC vs HIC): number of countries represented, number of respondents, and proportion of all respondents.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/table-005",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table A2.2. Geographic representation of participants in in-depth interviews on PrEP provider perspectives",
      "pageStart": 44,
      "pageEnd": 44,
      "target": "../tables/table-a2-2.csv",
      "narrative": "draft",
      "content": "Number of PrEP providers interviewed in depth in each WHO region and the countries they came from.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-360861/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 3: Summary of a review of PrEP services for people who inject drugs",
      "pageStart": 45,
      "pageEnd": 46,
      "target": "../sections/sec-033-annex-3-summary-of-a-review-of-prep-services-for.md",
      "narrative": null,
      "content": "review of PrEP services for \npeople who inject drugs\nBackground \nSince 2015, WHO has recommended offering TDF-based \noral PrEP to all people at substantial risk of HIV as part \nof combination HIV prevention, but little is known \nabout the extent to which this recommendation has \nbeen implemented for people who inject drugs. The \nobjectives of this study were to review literature on \nperspectives on and use of PrEP by people who inject \ndrugs and map global service delivery for this group.\nConclusion \nThis study indicates limited PrEP service availability for \nand use by people who inject drugs",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 3, summarizing a review of PrEP services for people who inject drugs, which found limited availability and use. It recommends expanding PrEP within harm reduction programmes, preferably community-based and peer-led, and lists service models found, before ending with WHO's contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-360861/blocks/figure-img-p046-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 46,
      "pageEnd": 46,
      "target": "../images/img-p046-1.webp",
      "narrative": "draft",
      "content": "ISBN barcode for 9789240053694.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
